New hope for Platinum-Resistant ovarian cancer: RC88 shows promise in early trial
NCT ID NCT06173037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other treatments. The results help determine if RC88 is a useful option for controlling this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200011, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Qilu Hospital of Shandong University
Jinan, Shangdong, 250012, China
-
Qingdao Central Hospital
Qingdao, Shandong, 266042, China
-
Second hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001, China
-
Shandong Cancer Hospital, Shandong Cancer Institute
Jinan, Shandong, 250117, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130031, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
The West China Second University Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430023, China
-
Xiangyang Central Hospital
Xiangyang, Hubei, 441021, China
-
Xingtai People's Hospital
Xingtai, Hebei, 054031, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?